Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNCENASDAQ:ENLVNYSE:IBIONASDAQ:IMNMNASDAQ:PHAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AENLVEnlivex Therapeutics$1.32-5.7%$3.36$1.15▼$4.59$24.51M1.02166,142 shs108,601 shsIBIOiBio$1.71-3.4%$0.00$1.02▼$27.80$5.95M-3.513.19 million shs95,243 shsIMNMImmunome$15.48-9.9%$23.03$4.44▼$30.96$924.00M1.66717,466 shs2.10 million shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics-5.41%-23.50%-65.60%-48.91%-52.05%IBIOiBio-5.85%-11.50%+40.48%+176,999,900.00%+176,999,900.00%IMNMImmunome-1.15%-18.27%-28.65%+27.26%+209.55%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+25.00%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics2.8685 of 5 stars3.55.00.00.01.80.81.3IBIOiBioN/AN/AN/AN/AN/AN/AN/AN/AIMNMImmunome1.6149 of 5 stars3.50.00.00.03.21.70.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCEConcert PharmaceuticalsN/AN/AN/AN/AENLVEnlivex Therapeutics3.00Buy$7.00430.30% UpsideIBIOiBioN/AN/AN/AN/AIMNMImmunome3.00Buy$32.67111.02% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest IBIO, CNCE, ENLV, IMNM, and PHAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.004/1/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $33.001/29/2024IMNMImmunomeLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/29/2024IMNMImmunomeSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.001/23/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $19.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AIBIOiBio$2.38M2.50N/AN/A$15.15 per share0.11IMNMImmunome$14.02M65.91N/AN/A$2.77 per share5.59PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)IBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/AIMNMImmunome-$106.81M-$5.39N/AN/AN/A-761.92%-69.74%-31.40%5/3/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest IBIO, CNCE, ENLV, IMNM, and PHAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCEConcert PharmaceuticalsN/A9.039.03ENLVEnlivex TherapeuticsN/A5.577.34IBIOiBio0.040.910.91IMNMImmunomeN/A6.636.63PHASPhaseBio PharmaceuticalsN/A0.470.47OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCEConcert Pharmaceuticals70.63%ENLVEnlivex Therapeutics1.02%IBIOiBio7.90%IMNMImmunome44.58%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipCNCEConcert Pharmaceuticals11.33%ENLVEnlivex Therapeutics12.28%IBIOiBio1.12%IMNMImmunome20.00%PHASPhaseBio Pharmaceuticals9.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableIBIOiBio263.48 million3.45 millionN/AIMNMImmunome3759.69 million47.76 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableIBIO, CNCE, ENLV, IMNM, and PHAS HeadlinesSourceHeadlineModified Release Neurology Therapeutics Report 202…pharmiweb.com - February 19 at 2:09 PMVelia Therapeutics Appoints Michael York as Chief Business Officerfinance.yahoo.com - December 14 at 8:55 AMLeading innovators in GLP-1 analogues for the pharmaceutical industrypharmaceutical-technology.com - November 6 at 7:00 AMAlcami Announces CEO Transitionfinance.yahoo.com - June 5 at 10:33 AM8-K: PhaseBio Pharmaceuticals Incmarketwatch.com - May 12 at 2:46 AMAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Resultsfinanznachrichten.de - March 31 at 6:59 PMBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinanznachrichten.de - March 31 at 1:59 PMBioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinance.yahoo.com - March 31 at 8:59 AMCardiomyopathy Medication Market Size and Forecast till 2031marketwatch.com - March 22 at 1:16 PMCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Datamarketwatch.com - February 28 at 1:24 PMJi Xing obtains global rights to cardiovascular candidate from Phasebiobioworld.com - February 9 at 7:59 AMBankrupt PhaseBio settles with investor-partner, handing off late-stage drugendpts.com - January 18 at 11:29 PMSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticalsbenzinga.com - January 17 at 12:24 PMBankruptcy court approves PhaseBio's $32.9M asset transfer dealbizjournals.com - January 5 at 7:47 PMBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assetsmarketwatch.com - November 8 at 12:22 AMShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.benzinga.com - November 4 at 2:57 PMWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - November 2 at 6:43 PMWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarketmsn.com - November 1 at 12:30 PMPhaseBio Pharmaceuticals 10% Owner Trades Company's Stockbenzinga.com - October 27 at 4:54 PMPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuitwsj.com - October 25 at 5:37 AMPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100Mbizjournals.com - October 25 at 5:37 AMPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code (Businesswire)avanza.se - October 24 at 12:07 PMAs top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bidendpts.com - October 24 at 12:07 PMPhaseBio Pharma Files For Chapter 11 Bankruptcy Protectionnasdaq.com - October 24 at 12:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsConcert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Enlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.iBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.ImmunomeNASDAQ:IMNMImmunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.